Platelet-Derived Growth Factor Is Associated with Progression of Symptomatic Intracranial Atherosclerotic Stenosis

• Published in: Journal of clinical neurology (Seoul, Korea) 2021, 17(1), , pp.70-76
• Main Authors: Kim, Kyeong Joon, Jeong, Sang Wuk, Ryu, Wi Sun, Kim, Dong Eog, Saver, Jeffrey L, Kim, Jong S, Kwon, Sun U
• Format: Article
• Language: English
• Subjects: Original; 신경과학
• ISSN: 1738-6586; 2005-5013
• DOI: 10.3988/jcn.2021.17.1.70

We aimed to determine the relationships of 33 biomarkers of inflammation, oxidation, and adipokines with the risk of progression of symptomatic intracranial atherosclerotic stenosis (ICAS). Fifty-two of 409 patients who participated in the TOSS-2 (Trial of Cilostazol in Symptomatic Intracranial Stenosis-2) showed progression of symptomatic ICAS in magnetic resonance angiography at 7 months after an index stroke. We randomly selected 20 patients with progression as well as 40 age- and sex-matched control patients. We serially collected blood samples at baseline, 1 month, and 7 months after an index stroke. Multiplex analysis of biomarkers was then performed. Demographic features and risk factors such as hypertension, diabetes, and smoking history were comparable between the two groups. Univariate analyses revealed that the levels of platelet-derived growth factor (PDGF)-AA [median (interquartile range)=1.64 (0.76-4.57) vs. 0.77 (0.51-1.71) ng/mL], PDGF-AB/BB [10.31 (2.60-25.90) vs. 2.35 (0.74-6.70) ng/mL], and myeloperoxidase [10.5 (7.5-22.3) vs. 7.8 (5.5-12.2) ng/mL] at 7 months were higher in the progression group. In the multivariate analysis using logistic regression, the PDGF AB/BB level at 7 months was independently associated with the progression of ICAS ( =0.02). The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS.